Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) has been assigned a consensus recommendation of “Hold” from the nineteen ratings firms that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $66.1875.
A number of equities analysts recently weighed in on INSP shares. JPMorgan Chase & Co. upped their target price on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Truist Financial reissued a “hold” rating and issued a $62.00 price target (up from $54.00) on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. UBS Group started coverage on Inspire Medical Systems in a report on Tuesday, July 28th. They issued a “sell” rating and a $39.00 price target on the stock. Wells Fargo & Company reduced their price objective on Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 5th. Finally, Freedom Capital upgraded Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th.
View Our Latest Stock Report on Inspire Medical Systems
Inspire Medical Systems Stock Performance
Inspire Medical Systems (NYSE:INSP – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The firm’s revenue was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, sell-side analysts anticipate that Inspire Medical Systems will post 1.24 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Inspire Medical Systems news, insider Jason P. Kelly sold 963 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total transaction of $57,346.65. Following the completion of the transaction, the insider owned 18,985 shares of the company’s stock, valued at $1,130,556.75. This represents a 4.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.20% of the stock is currently owned by company insiders.
Institutional Trading of Inspire Medical Systems
A number of institutional investors have recently made changes to their positions in INSP. CWM LLC grew its position in Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after purchasing an additional 242 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Inspire Medical Systems by 1,115.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after buying an additional 580 shares in the last quarter. Havemeyer Place LP acquired a new position in shares of Inspire Medical Systems during the 4th quarter worth about $39,000. V Square Quantitative Management LLC acquired a new position in shares of Inspire Medical Systems during the 4th quarter worth about $40,000. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after buying an additional 205 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.
About Inspire Medical Systems
Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.
The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.
Featured Articles
- Five stocks we like better than Inspire Medical Systems
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
